Speed, duration, and retail shifts reshape tick prevention talk

A new Fear Free article is putting fresh attention on a familiar but clinically important question: not all tick preventives perform the same way over time, and the difference between “works” and “works fast enough” may matter in practice. In “Tick-Tock: Comparing Speed and Duration of Tick Treatments,” Jack Meyer frames the issue around rising tick-borne disease pressure in the U.S. and highlights a brand-supported comparison in which Elanco’s Credelio (lotilaner) outperformed afoxolaner and sarolaner on speed of kill against lone star ticks and on sustained efficacy through the monthly dosing period. (fearfree.com)

That message is landing at a time when parasite risk remains a moving target. CAPC’s 2025 Pet Parasite Forecast warned that Lyme disease, anaplasmosis, ehrlichiosis, and heartworm continue to spread, with tick-borne disease risk expanding geographically and dogs serving as useful sentinels for human exposure. Fear Free’s article echoes that broader concern, noting that tick-borne disease prevalence is increasing across the country and tying prevention not only to canine health, but also to household stress and the human-animal bond. (capcvet.org)

The key evidence in the Fear Free piece comes from an Elanco-backed, head-to-head study described as “data on file.” According to the article, 32 dogs were infested with 50 lone star ticks each, then treated 48 hours later with lotilaner, afoxolaner, sarolaner, or left untreated as controls. Fear Free reports that lotilaner delivered the fastest speed of kill, was “twice as fast” as the competing products in that study, and was the only treatment group to achieve at least 90% efficacy at every 24-hour evaluation over 30 days. The article also argues that lone star ticks are a meaningful comparator because they are relatively harder to kill and can carry pathogens of concern. Because the underlying dataset does not appear to be publicly published in the article itself, veterinarians should read the claims as promotional but still potentially useful when comparing label positioning and discussing expectations with clients. (fearfree.com)

Fear Free also leans into the practical counseling angle. It says some pathogens may begin transmitting within 3 to 24 hours after attachment, making rapid kill a clinically relevant distinction rather than a marketing footnote. It further argues that chewable administration may reduce medication-related stress for dogs and pet parents, and that more consistent efficacy across the dosing interval may offer some reassurance when clients are late on monthly redosing. Those are familiar talking points in parasite medicine, but they resonate more now as clinics try to improve compliance in an environment where exposure risk is broadening and pet parents are asking more detailed questions about onset, duration, and safety. (fearfree.com)

At the same time, the retail market is signaling consumer demand for adjunctive, non-chemical tick products. Pet Age reported on March 31, 2026, that Tick Solutions Global’s TiCK MiTT will enter more than 900 Petco stores in an exclusive teal version beginning in spring 2026. Petco’s product page describes the mitt as a reusable tool for removing loose ticks from fur, skin, clothing, and gear, but it also includes an important disclaimer: the product does not remove embedded ticks and does not prevent tick-borne disease. That distinction matters. For veterinary teams, products like this may fit into a layered prevention conversation, especially for outdoor households, but they shouldn’t be conflated with systemic or labeled preventive protection. (petage.com)

Industry and regulatory context add more nuance. Elanco separately announced in late 2025 that it had expanded Credelio and Credelio Quattro labels to include protection against Lyme disease and coverage involving the invasive longhorned tick, underscoring how manufacturers are trying to differentiate in a crowded isoxazoline category. But FDA’s standing safety communication remains relevant: isoxazoline products, including lotilaner, afoxolaner, fluralaner, and sarolaner, have been associated with neurologic adverse reactions such as tremors, ataxia, and seizures in some animals. In other words, the current market conversation is not just about efficacy curves, but also about case selection, informed consent, and individualized risk-benefit decisions. (investor.elanco.com)

Why it matters: For veterinary professionals, this story is a reminder that tick prevention discussions are getting more sophisticated. Clinics are no longer just recommending “a tick product”; they’re increasingly being asked to explain why one product, one route, or one dosing interval may be preferable for a given dog and household. Speed of kill is especially relevant in higher-risk regions and for pet parents who hike, hunt, travel, or live where lone star, black-legged, or brown dog ticks are common. But the bigger opportunity may be communication: helping pet parents understand that year-round prevention, regular tick checks, environmental management, and prompt removal of attached ticks all play different roles, and that retail accessories are complements, not replacements, for evidence-based prevention. (capcvet.org)

What to watch: The next thing to watch is whether the comparative lotilaner data moves from “data on file” into peer-reviewed publication, and whether more clinics begin explicitly segmenting tick recommendations by transmission window, local vector pressure, and tolerance for adverse-event risk. Also worth watching is how mass retail partnerships like Petco’s shape pet parent expectations around chemical-free tick control, and whether that creates more demand for veterinary guidance on what these products can, and can’t, do. (fearfree.com)